Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 2/20 | 0.48 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.48 |
| ▸ | MMP2 | P08253 | 7/20 | 0.47 |
| ▸ | CA12 | O43570 | 5/20 | 0.47 |
| ▸ | CA1 | P00915 | 5/20 | 0.47 |
| ▸ | CA2 | P00918 | 5/20 | 0.47 |
| ▸ | CA9 | Q16790 | 5/20 | 0.47 |
| ▸ | MMP1 | P03956 | 2/20 | 0.47 |
| ▸ | MMP8 | P22894 | 2/20 | 0.47 |
| ▸ | MMP3 | P08254 | 1/20 | 0.47 |
| ▸ | FDPS | P14324 | 3/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (Cyclooctylamino)Methylenediphosphonic Acid SCHEMBL9777403 | 1.00 | ANPEP (0.48) | ANPEPERAP2MMP2CA12CA1 | |
| (Cyclohexylamino)Methylenediphosphonic Acid SCHEMBL8370913 | 1.00 | ANPEP (0.48) | ANPEPERAP2MMP2CA12CA1 | |
| (Cyclopentylamino)Methylenediphosphonic Acid SCHEMBL9626232 | 0.98 | ANPEP (0.46) | ANPEPERAP2MMP2CA12CA1 | |
| Incadronic Acid SCHEMBL2898450 | 0.96 | ANPEP (0.46) | ANPEPERAP2MMP2CA12CA1 | |
| (Cyclobutylamino)Methylenediphosphonic Acid SCHEMBL9626988 | 0.93 | MMP2 (0.45) | ANPEPERAP2MMP2CA12CA1 | |
| (Cyclopropylamino)Methylenediphosphonic Acid SCHEMBL9627717 | 0.88 | MMP2 (0.41) | ANPEPERAP2MMP2CA12CA1 | |
| Incadronic Acid SCHEMBL2898447 | 0.85 | ANPEP (0.41) | ANPEPERAP2MMP2CA12CA1 | |
| Incadronic Acid SCHEMBL29355743 | 0.81 | MMP2 (0.42) | ANPEPERAP2MMP2CA12CA1 | |
| SCHEMBL18657116 | 0.80 | ANPEP (0.47) | ANPEPERAP2MMP2CA12CA1 | |
| SCHEMBL10419330 | 0.78 | HDAC3 (0.33) | ANPEPERAP2MMP2MMP1MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3041 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12529035-B1 | Method for producing induced pluripotent stem cells | NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY (JP) | 2026-01-20 | — | — | US | claimed |
| US-20260000734-A1 | METHODS FOR EXPANDING AND ACTIVATING yo T CELLS FOR THE TREATMENT OF CANCER AND RELATED MALIGNANCIES | IMMATICS US INC (US) | 2026-01-01 | — | — | US | claimed |
| WO-2025261951-A1 | COMBINATION THERAPY WITH AN ANTI-CA19-9 ANTIBODY AND FOLFIRINOX IN THE TREATMENT OF CANCER | BioNTech SE (DE) | 2025-12-26 | — | — | WO | claimed |
| EP-3717634-B1 | METHODS FOR ACTIVATING, MODIFYING AND EXPANDING GAMMA DELTA T CELLS FOR THE TREATMENT OF CANCER AND RELATED MALIGNANCIES | IMMATICS US INC (US) | 2025-10-15 | — | — | EP | claimed |
| US-12440541-B2 | Methods for expanding and activating γσ T cells for the treatment of cancer and related malignancies | Immatics US, Inc. (US) | 2025-10-14 | — | — | US | claimed |
| EP-4602049-A1 | SOS1 INHIBITORS | Bayer Aktiengesellschaft (DE) | 2025-08-20 | — | — | EP | claimed |
| EP-4587439-A1 | SULFONE-SUBSTITUTED PYRIDO[3,4-D]PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | Bayer Aktiengesellschaft (DE) | 2025-07-23 | — | — | EP | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| US-20250154170-A1 | FUSED PYRIMIDINES AS KRAS INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2025-05-15 | — | — | US | claimed |
| WO-2025021997-A1 | NEW MAP4K1 INHIBITORS | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2025-01-30 | — | — | WO | claimed |
| EP-0600834-A1 | Use of methanebisphosphonic acid derivatives for the manufacture of a medicament for fracture healing | CIBA-GEIGY AG (CH) | 1994-06-08 | — | — | EP | claimed |
| WO-1994000129-A1 | USE OF PHOSPHONATES FOR THE TREATMENT OF OSTEOPOROSIS | PROCTER & GAMBLE PHARMACEUTICALS, INC. (US) | 1994-01-06 | — | — | WO | claimed |
| EP-0573604-A1 | METHODS FOR THE TREATMENT OF OSTEOPOROSIS. | NORWICH EATON PHARMA (US) | 1993-12-15 | — | — | EP | claimed |
| EP-0550385-A1 | Oral pharmaceutical compositions containing derivatives of methane-diphosphonic acid and 18-crown-6 ethers | CIBA-GEIGY AG (CH) | 1993-07-07 | — | — | EP | claimed |
| WO-1993011786-A1 | METHODS FOR THE TREATMENT OF OSTEOPOROSIS USING BISPHOSPHONATES AND PARATHYROID HORMONE | PROCTER & GAMBLE PHARMACEUTICALS, INC. (US) | 1993-06-24 | — | — | WO | claimed |
| WO-1992014474-A1 | METHODS FOR THE TREATMENT OF OSTEOPOROSIS | NORWICH EATON PHARMACEUTICALS, INC. (US) | 1992-09-03 | — | — | WO | claimed |
| EP-0325482-B1 | (CYCLOALKYLAMINO)METHYLENEBISPHOSPHONIC ACIDS AND MEDICINES CONTAINING THEM | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1992-04-01 | — | — | EP | claimed |
| US-5041428-A | Bone resorption inhibitor, antiarthritic agent | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1991-08-20 | — | — | US | claimed |
| US-4970335-A | ANTIARTHRITIC AGENTS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1990-11-13 | — | — | US | claimed |
| EP-0325482-A1 | (Cycloalkylamino)methylenebisphosphonic acids and medicines containing them | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1989-07-26 | — | — | EP | claimed |